平安好醫生(01833.HK)續漲12%屢創上市新高
美國出現首宗武漢肺炎確診個案,武漢新型冠狀病毒感染肺炎已蔓延至最少13省,全國確診個案已增至440宗,死亡病例增至9宗,澳門也出現首宗確診個案。
獲麥格理升價至78元的平安好醫生(01833.HK)連升第六天兼第二天創上市新高,股價承昨天逆大跌市漲逾6%破頂強勢,午後升幅擴至12%,報74.9元即市新高,成交已達1,109萬股,涉資7.9億元。
麥格理昨天報告料平安好醫生去年下半年收入按年增長18%,若撇除2018年下半年企業採購之影響,按年增長實為41%。該行相信,會員銷售將持續帶動高毛利網上醫療服務,去年下半年及今年相關業務按年增長可分別達111%及81%,毛利前景亦將持續改善。預計今年收入按年增長將反彈至35%,上調公司2019-2021年每股盈測,料2021年每股盈利0.12元人民幣。重申「跑贏大市」,目標價升20%至78元。(sz)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.